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Kidney-Failure Risk Projection for the Living Kidney-Donor Candidate
To the Editor: Grams et al. (Feb. 4 issue)1 quanti-
fied the associations between “13 distinct demo-
graphic and health characteristics” and end-stage 
renal disease among low-risk members of seven 
general population cohorts in order to estimate 
the long-term risk of end-stage renal disease 
among kidney-donor candidates. Two important 
factors were not considered: biologic and house-
hold relatedness to a person with end-stage renal 
disease. Most living kidney donors are geneti-
cally related to their recipients, and heredity is a 
known contributor to kidney disease.2 Further-
more, many related donors and their recipients 
grow up following similar dietary, exercise, and 
other health-related practices, factors that also 
affect the incidence of end-stage renal disease.3-5 
Grams et al. acknowledge the importance of ge-
netic and environmental influences when they 
note that these influences may have contributed 
to the variation in risk associated with race un-
covered in their study. The failure to incorporate 
these two factors into their equations renders the 
authors’ estimates of the risk of end-stage renal 
disease suspect at best.
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To the Editor: In the simulation conducted by 
Grams et al. to predict the risk of end-stage renal 
disease after kidney donation, the estimated glo-
merular filtration rate (eGFR) is an important vari-
able. However, the use of the eGFR (incorporated 
by means of equations based on creatinine level) 
rather than measured GFR (incorporated by means 
of a reference method) is questionable. The eGFR 
lacks precision in the range of the GFR considered 
(i.e., more than 60 ml per minute per 1.73 m2 of 
body-surface area).1,2 Age is also an important 
variable in the calculation of the eGFR equation, 
and its use could introduce an association with a 
false positive result, especially in simulations, 
since age is one of the major risk factors for end-
stage renal disease. Finally, in African Americans, 
an ancestry coefficient appears in creatinine-based 
eGFR equations. However, this coefficient has 
been criticized as being inappropriately high,3,4 
especially when applied to GFR values over 60 ml 
per minute per 1.73 m2. Such an overestimation 
of the eGFR in African Americans could explain 
at least in part the higher risk observed among 
these patients, since their true GFR is actually 
lower than that calculated by means of the eGFR. 
Moreover, these ancestral coefficients are inac-
curate in non–American-African populations.4 
For these reasons, we believe that measurement 
of the GFR in the evaluation of potential kidney 
donors to be an important, if not mandatory, step.
Pierre Delanaye, M.D., Ph.D.
University of Liège Hospital 
Liège, Belgium 
pierre_delanaye@ yahoo . fr
this week’s letters
2093 Kidney-Failure Risk Projection for the Living 
Kidney-Donor Candidate
2095 Postmenopausal Osteoporosis
2097 Physicians and Youth Tackle Football
The New England Journal of Medicine 
Downloaded from nejm.org on May 26, 2016. For personal use only. No other uses without permission. 
 Copyright © 2016 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 374;21 nejm.org May 26, 20162094
Richard J. Glassock, M.D.
Geffen School of Medicine at UCLA 
Los Angeles, CA
No potential conflict of interest relevant to this letter was re-
ported.
1. Delanaye P, Mariat C. The applicability of eGFR equations to 
different populations. Nat Rev Nephrol 2013; 9: 513-22.
2. Barri YM, Parker T III, Daoud Y, Glassock RJ. Definition of 
chronic kidney disease after uninephrectomy in living donors: 
what are the implications? Transplantation 2010; 90: 575-80.
3. Delanaye P, Mariat C, Maillard N, Krzesinski JM, Cavalier E. 
Are the creatinine-based equations accurate to estimate glomer-
ular filtration rate in African American populations? Clin J Am 
Soc Nephrol 2011; 6: 906-12.
4. Flamant M, Vidal-Petiot E, Metzger M, et al. Performance of 
GFR estimating equations in African Europeans: basis for a 
lower race-ethnicity factor than in African Americans. Am J Kid-
ney Dis 2013; 62: 182-4.
DOI: 10.1056/NEJMc1603007
To the Editor: Grams et al. applied risk esti-
mates to actual kidney donors, showing that 
their risk of end-stage renal disease would have 
been less had they not donated a kidney. Two 
other recent studies indicate that the relative risk 
of end-stage renal disease after kidney donation 
is increased.1,2 A very important distinction that 
the Grams et al. note is the difference between 
relative risk and absolute risk. Since end-stage 
renal disease is relatively rare, a high relative risk 
may be equivalent to a low absolute risk if the 
baseline risk is sufficiently low.
In light of this consideration, we were disap-
pointed when we attempted to use the online 
risk calculator. Instead of multiplying the base-
line risks before donation by the known relative 
risks, the authors stated only that the mean ab-
solute increase was 0.27%. We feel that absolute 
risk should be given. In Norway, as a conse-
quence of our previous study on risk in kidney 
donors,2 the increased risks of end-stage renal 
disease and death are now disclosed to all po-
tential donors.
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The authors reply: We agree that several fac-
tors not captured in our model may affect the 
long-term risk of end-stage renal disease in living 
kidney-donor candidates. As Spital notes, these 
risks include heritable and environmental factors. 
Risks attributable to these factors have not been 
captured in existing studies of healthy persons. 
Our online tool takes full advantage of the avail-
able data. Although it should help clinicians ap-
preciate the relationships between many predo-
nation characteristics and the long-term risk of 
end-stage renal disease, the tool is in no way 
meant to replace a comprehensive evaluation of 
a donor candidate by an expert physician who 
carefully considers the circumstances of each in-
dividual candidate. Donor candidates with a fam-
ily history of kidney disease (and in particular 
younger candidates with such a history) would be 
expected to have a higher risk of end-stage renal 
disease than indicated by our projection.1 As 
Mjøen and Holdaas suggest, a candidate who 
chooses to proceed with kidney donation will 
face additional risk from the donation itself — 
including a risk of end-stage renal disease that 
may be at least four times as high as it would 
have been if the candidate had not proceeded 
with the donation.2,3 Estimates of the risks of 
donation according to a given clinical profile are 
not yet available, but we agree that the develop-
ment of such estimates should be a high priority 
for future research. We will update the online 
tool once estimates are available.
Delanaye and Glassock question the use of the 
eGFR in model development. We used the eGFR 
because we are unaware of any long-running 
cohort studies of healthy persons followed for 
end-stage renal disease that include measured 
GFR. Although there may be uncertainty with 
regard to the best way to incorporate age and sex 
in the estimation of the GFR, we are not aware 
of any data that support the suggestion that 
there is systematic misclassification according 
to age, race, or sex. Our model is internally con-
sistent and calibrated to measures of observed 
risk in the U.S. population within the categories 
of age, race, and sex, irrespective of the eGFR. 
The question of whether a direct measurement 
of the GFR is necessary in all donor candidates 
is currently under debate,4 but the increased risk of 
kidney failure among African Americans as com-
pared with whites has also been noted among 
U.S. donors, in whom creatinine clearances are 
generally measured at the time of evaluation.2
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Our ultimate goal is to make donor-candidate 
education and acceptance more empiric and defen-
sible. Our study provides a framework for donor 
evaluation that is centered on the simultaneous 
consideration of many clinical factors relevant to 
the risk of end-stage renal disease, but its appli-
cation requires insight and sensitivity to nuance 
on the part of the clinician. Suggested framing 
is described in detail in the KDIGO (Kidney 
Disease: Improving Global Outcomes) guidelines 
for clinical practice.5 We see our work as a 
starting point and advocate strongly for contin-
ued efforts to improve the precision and gener-
alizability of estimates of risk before and after 
donation.
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Postmenopausal Osteoporosis
To the Editor: According to the results of two 
trials presented in Table 3 of the article by Black 
and Rosen (Jan. 21 issue),1 the first 3 years of 
bisphosphonate use are beneficial for the preven-
tion of fracture. However, the data presented in 
the table are misleading. The steep increase in the 
incidence of atypical fracture with prolonged bis-
phosphonate use is concomitant with little or no 
added efficacy in the prevention of fracture. On 
the basis of population-based data,2 rather than 
theoretical calculations,1 the risk of atypical fem-
oral fractures for patients who receive 4 years of 
treatment is 126 times as high as the risk for 
those who did not receive treatment, which cor-
responds to a number needed to harm of 909 per 
year (odds ratio for the fifth year, 116).2 When all 
available data on the efficacy of treatment for the 
prevention of hip fracture are considered — not 
just two out of all randomized, controlled trials 
— the number needed to treat (NNT) is 501 per 
year for the initial 3 years of use.3 Because the 
extension of treatment beyond 5 years does not 
appear to prevent nonvertebral or hip fractures,4 
the NNT for a sixth year would be high — close 
to infinity. For the fourth and fifth years, the 
NNT would lie somewhere between 501 and in-
finity. It is uncertain whether there is a positive 
benefit:risk ratio when the duration of treatment 
is longer than 3 to 4 years. Recently suggested 
widening of the treatment indications5 will in-
crease the NNT. A consequence may be that the 
risks will outweigh the benefits even after treat-
ment of shorter duration.
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To the Editor: Black and Rosen suggest that the 
discontinuation of bisphosphonates after 5 years 
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